Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company’s clinical advancements and future milestones. Tardio highlighted the differentiated pipeline, including vidofludimus calcium, which addresses both relapsing and progressive forms of multiple sclerosis. The compound's dual mechanisms, anti-inflammatory and neuroprotective, could revolutionise MS treatment with its safety and efficacy profile.
He also discussed the significant milestones achieved in 2024, such as the positive interim analysis of the ENSURE trials and the anticipation of the CALLIPER study results in April 2025. Tardio emphasised the growing visibility of Immunic’s programs through publications, conferences, and strengthened leadership, positioning the company for impactful progress.
Quoting Tardio: “Vidofludimus calcium is the first oral disease-modifying therapy that could treat both relapsing and progressive forms of the disease.” He also stressed its unique mechanisms targeting unmet needs in the MS space.